Second European Medicines Agency (EMA) and EUCOPE bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 29 November 2023

Human medicines European public assessment report (EPAR): Plavix, clopidogrel, Stroke;Peripheral Vascular Diseases;Atrial Fibrillation;Myocardial Infarction;Acute Coronary Syndrome, Date of authorisation: 15/07/1998, Revision: 50, Status: Authorised

Second European Medicines Agency (EMA) and EUCOPE bilateral meeting, European Medicines Agency , from 29/11/2023 to 29/11/2023

Human medicines European public assessment report (EPAR): Cialis, tadalafil, Erectile Dysfunction, Date of authorisation: 12/11/2002, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Ozawade, pitolisant, Sleep Apnea, Obstructive, Date of authorisation: 01/09/2021, Revision: 3, Status: Authorised

Omega-3 fatty acid ethyl esters

Withdrawn application: Iclusig, ponatinib, Date of withdrawal: 11/08/2023, Post-authorisation

Human medicines European public assessment report (EPAR): Ocaliva, obeticholic acid, Liver Cirrhosis, Biliary, Date of authorisation: 12/12/2016, Revision: 17, Status: Authorised

Oral retinoids: List of nationally authorised medicinal products - EMEA/H/N/PSR/J/0002

Veterinary good pharmacovigilance practices (VGVP)